BR112015025662A2 - terapia de combinação seletiva de tumor - Google Patents

terapia de combinação seletiva de tumor

Info

Publication number
BR112015025662A2
BR112015025662A2 BR112015025662A BR112015025662A BR112015025662A2 BR 112015025662 A2 BR112015025662 A2 BR 112015025662A2 BR 112015025662 A BR112015025662 A BR 112015025662A BR 112015025662 A BR112015025662 A BR 112015025662A BR 112015025662 A2 BR112015025662 A2 BR 112015025662A2
Authority
BR
Brazil
Prior art keywords
treatment
therapies described
abstract
selective
combination therapy
Prior art date
Application number
BR112015025662A
Other languages
English (en)
Inventor
A Boothman David
I Parkinson Elisabeth
Gao Jimming
S Bair Joseph
Cao Lifen
j hergenrother Paul
Ma Xinpeng
Huang Xiumei
Luo Xiuquan
R Moore Zachary
Original Assignee
Univ Texas
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Univ Illinois filed Critical Univ Texas
Publication of BR112015025662A2 publication Critical patent/BR112015025662A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

abstract the therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. the combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of nqo1. tradução do resumo resumo patente de invenção: "terapia de combinação seletiva de tumor". as terapias aqui descritas podem ser seletivamente letais na direção de uma variedade de diferentes tipos de células de câncer e condições de câncer em um sujeito. as terapias de combinação aqui descritas podem ser úteis para o gerenciamento, tratamento, controle, ou tratamento adjunto de doenças, onde a letalidade seletiva é benéfica em quimioterapia, particularmente onde a doença é acompanhada por elevados níveis de nqo1.
BR112015025662A 2013-04-09 2014-04-08 terapia de combinação seletiva de tumor BR112015025662A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361810008P 2013-04-09 2013-04-09
PCT/US2014/033400 WO2014168991A1 (en) 2013-04-09 2014-04-08 Tumor-selective combination therapy

Publications (1)

Publication Number Publication Date
BR112015025662A2 true BR112015025662A2 (pt) 2017-07-18

Family

ID=51689971

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015025662A BR112015025662A2 (pt) 2013-04-09 2014-04-08 terapia de combinação seletiva de tumor

Country Status (15)

Country Link
US (2) US10272099B2 (pt)
EP (1) EP2984184B1 (pt)
JP (2) JP6615746B2 (pt)
CN (2) CN111481551B (pt)
AU (2) AU2014251043B2 (pt)
BR (1) BR112015025662A2 (pt)
CA (1) CA2909091C (pt)
DK (1) DK2984184T3 (pt)
ES (1) ES2853973T3 (pt)
HU (1) HUE052930T2 (pt)
MX (2) MX2015014282A (pt)
PL (1) PL2984184T3 (pt)
PT (1) PT2984184T (pt)
WO (1) WO2014168991A1 (pt)
ZA (1) ZA201507755B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111481551B (zh) * 2013-04-09 2023-06-09 伊利诺伊大学董事会 肿瘤选择性联合疗法
KR20190025646A (ko) * 2016-06-27 2019-03-11 시스템즈 온콜로지, 엘엘씨 병용 화학요법
WO2019113345A1 (en) * 2017-12-06 2019-06-13 Spyro Mousses Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases
WO2019156684A1 (en) * 2018-02-12 2019-08-15 Solugen, Inc. Hydrogen peroxide production method, system, and apparatus
CA3095709A1 (en) 2018-04-05 2019-10-10 Noviga Research Ab Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
JP7447013B2 (ja) * 2018-04-09 2024-03-11 ユンジン ファーム．カンパニー、リミテッド １，２－ナフトキノン誘導体化合物を含む固形癌または血液癌の予防または治療用薬学組成物
CA3130513A1 (en) * 2019-03-18 2020-09-24 The Board Of Regents Of The University Of Texas System Tumor-selective combination therapy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906562A (en) * 1984-12-21 1990-03-06 Oncogen Monocolonal antibodies and antigen for human non-small cell lung carcinomas
ES2088822B1 (es) * 1994-02-24 1997-08-01 Univ Madrid Complutense Nuevos derivados antraquinonicos con actividad antitumoral y sus aplicaciones.
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
FR2797446B1 (fr) * 1999-08-13 2001-11-02 Lafon Labor Derives de phenanthroline-7-ones et leurs applications en therapeutique
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
JP2005501848A (ja) * 2001-08-15 2005-01-20 アイコス コーポレイション ２ｈ−フタラジン−１−オンおよびその使用方法
CN100566711C (zh) * 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
US6890950B2 (en) * 2002-04-23 2005-05-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
BRPI0408996A (pt) 2003-03-31 2006-03-28 Pfizer saia de inibidores tricìclicos de poli(adpp-ribose) polimerases
US8614228B2 (en) * 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
WO2006024545A1 (en) * 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
WO2007092963A1 (en) * 2006-02-09 2007-08-16 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment involving determination of tumor enzyme level
EP2173333B1 (en) 2006-12-29 2018-06-27 Tracon Pharmaceuticals, Inc. Combinations of antifolate agent and methoxyamine in the treatment of cancer
JP2011503111A (ja) * 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
EP2250282A4 (en) 2008-02-04 2011-05-18 Bipar Sciences Inc METHOD FOR THE DIAGNOSIS AND TREATMENT OF PARP-MEDIATED DISEASES
KR20130044382A (ko) * 2010-03-01 2013-05-02 마이렉시스 인코포레이티드 화합물 및 그의 치료 용도
ES2602475T3 (es) * 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
US9081428B2 (en) * 2010-04-23 2015-07-14 Psion Inc. Apparatus and method for impact resistant touchscreen display module
CA2811015A1 (en) * 2010-09-15 2012-03-22 Almac Diagnostics Limited Molecular diagnostic test for cancer
TR201807363T4 (tr) * 2010-09-22 2018-06-21 Univ Texas Hedefleyici nqo1 i içeren kanser tedavi yöntemleri.
US20120142650A1 (en) * 2010-12-07 2012-06-07 John Hollingsworth Method for treating lung disease
US20120208767A1 (en) * 2011-02-14 2012-08-16 University Of Maryland, Baltimore Method to Detect or Treat Painful Bladder Syndrome based on Relation to Quinone Oxidoreductase 1
EP3219949B1 (en) * 2011-09-12 2019-03-20 Cummins Emission Solutions, Inc. A kit for installing an aftertreatment system package for exhaust gas
US9233960B2 (en) 2011-10-14 2016-01-12 The Board Of Trustees Of The University Of Illinois Compounds and anti-tumor NQO1 substrates
CN111481551B (zh) * 2013-04-09 2023-06-09 伊利诺伊大学董事会 肿瘤选择性联合疗法

Also Published As

Publication number Publication date
ZA201507755B (en) 2019-11-27
JP6615746B2 (ja) 2019-12-04
JP6719620B2 (ja) 2020-07-08
US20180099002A1 (en) 2018-04-12
WO2014168991A1 (en) 2014-10-16
DK2984184T3 (da) 2021-03-01
PT2984184T (pt) 2021-02-24
EP2984184B1 (en) 2020-11-25
AU2014251043A1 (en) 2015-11-05
PL2984184T3 (pl) 2021-06-14
JP2016516775A (ja) 2016-06-09
CN111481551B (zh) 2023-06-09
JP2019163309A (ja) 2019-09-26
US10576096B2 (en) 2020-03-03
EP2984184A4 (en) 2016-11-30
ES2853973T3 (es) 2021-09-20
HUE052930T2 (hu) 2021-05-28
CA2909091C (en) 2021-11-02
CN105658809A (zh) 2016-06-08
CA2909091A1 (en) 2014-10-16
CN105658809B (zh) 2020-03-27
CN111481551A (zh) 2020-08-04
AU2014251043B2 (en) 2020-01-16
US20160030457A1 (en) 2016-02-04
US10272099B2 (en) 2019-04-30
MX2021000828A (es) 2021-03-25
AU2020202453B2 (en) 2022-04-14
MX2015014282A (es) 2016-07-20
AU2020202453A1 (en) 2020-05-28
EP2984184A1 (en) 2016-02-17

Similar Documents

Publication Publication Date Title
BR112015025662A2 (pt) terapia de combinação seletiva de tumor
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112015025424A2 (pt) tratamento de câncer usando terapias de combinação de coenzima q10
BR112015028845A2 (pt) compostos para a modulação da quinase e indicações da mesma
BR112016002465A2 (pt) terapia da combinação para o tratamento de câncer
EA201890641A3 (ru) Стимуляторы sgc
BR112016006978A2 (pt) inibidores de tirosina quinase de bruton
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
CR11717A (es) Terapia de combinacion con antagonistas de c-met y egfr
BR112013023774A2 (pt) inibidores de glicosilceramida sintase
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
WO2014145642A3 (en) Nrf2 small molecule inhibitors for cancer therapy
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
AR087918A1 (es) Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112015021423A2 (pt) métodos de tratamento de câncer, de células de câncer e de câncer resistente a antagonista de egfr, métodos de aumento da sensibilidade e da eficácia de tratamento de câncer e métodos de atraso, de tratamento de indivíduos com câncer e de extensão
BR112018013063A2 (pt) combinação terapêutica inibidora de bromodomínio e proteína extra-terminal
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
BR112016024691A2 (pt) ciclo-hexanocarboxamida com propriedades de resfriamento
BR112016017317A8 (pt) composto, antagonista de trpa1, medicamento, e, método para profilaxia e/ou tratamento de uma doença que envolve trpa1
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
PE20151751A1 (es) Metodos de tratamiento de la deficiencia de hierro con pirofosfato ferrico soluble

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]